ERBB2 and ovarian cancer: The CXCL12–CXCR4 signaling pathway transactivates Her2-neu to stimulate invasive and metastatic signals in breast [32], esophageal [33], lung [34], and prostate [35] cancers, as well as ovarian cancers [36].